Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2016 | Pages:
52 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Pipeline Review, H1 2016', provides in depth analysis on Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted pipeline therapeutics. The report provides comprehensive information on the Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - The report reviews Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics and enlists all their major and minor projects - The report assesses Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Overview 6 Therapeutics Development 7 Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Products under Development by Stage of Development 7 Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Products under Development by Therapy Area 8 Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Products under Development by Indication 9 Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Products under Development by Companies 12 Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Therapeutics Assessment 14 Assessment by Monotherapy/Combination Products 14 Assessment by Mechanism of Action 15 Assessment by Route of Administration 16 Assessment by Molecule Type 18 Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Companies Involved in Therapeutics Development 20 Genentech, Inc. 20 Protagonist Therapeutics Inc. 21 Takeda Pharmaceutical Company Limited 22 Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Drug Profiles 23 etrolizumab - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 PTG-100 - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 Small Molecule to Antagonize Integrin Alpha4 and Beta7 for Inflammatory Bowel Disease - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 Small Molecules to Antagonize Integrin Alpha4 and Integrin Beta7 for Inflammatory Bowel Disease - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 vedolizumab - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Dormant Projects 34 Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Discontinued Products 35 Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Featured News & Press Releases 36 May 24, 2016: Takeda Presents Analyses From Vedolizumab Data in Ulcerative Colitis at 2016 Digestive Disease Week Annual Meeting 36 May 17, 2016: Protagonist Therapeutics to Present New Data on PTG-100 at Digestive Disease Week 2016 37 Mar 19, 2016: New Data Presented at European Crohn's and Colitis Organisation Scientific Meeting on Efficacy of Long-Term Vedolizumab Treatment 37 Jan 08, 2016: Protagonist Therapeutics Initiates Phase 1 Study with Oral Peptide PTG-100 38 Oct 19, 2015: Takeda Presents Vedolizumab Data at the 2015 American College of Gastroenterology Annual Meeting and United European Gastroenterology Week 39 Jul 10, 2015: NICE recommends treatment for severe Crohn's disease 41 May 19, 2015: New biologic treatment for ulcerative colitis ENTYVIO (vedolizumab) now available in Canada after key work by Canadian researchers 41 May 19, 2015: New biologic treatment for ulcerative colitis ENTYVIO now available in Canada after key work by Canadian researchers 42 Mar 13, 2015: Treatment for chronic painful bowel condition to get NHS funding approval 44 Nov 10, 2014: Encycle Therapeutics developing lead molecule to tackle inflammatory bowel disease 44 Nov 10, 2014: Partnership announcement to tackle inflammatory bowel disease 45 Oct 02, 2014: Takeda Presents New Interim Phase 3 Maintenance Data that Support the Long-Term Efficacy of Vedolizumab in Patients with Ulcerative Colitis and Crohn's Disease 46 Jun 16, 2014: ENTYVIO (vedolizumab) Now Available in the United States for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis and Crohn's Disease 47 May 28, 2014: Takeda Receives European Commission Marketing Authorisation for Entyvio (vedolizumab) for the Treatment of Ulcerative Colitis and Crohn's Disease 48 May 20, 2014: FDA Approves Takeda's Entyvio for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis or Crohn's Disease 49 Appendix 51 Methodology 51 Coverage 51 Secondary Research 51 Primary Research 51 Expert Panel Validation 51 Contact Us 51 Disclaimer 52
List of Tables
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Indication, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Products under Development by Companies, H1 2016 13 Assessment by Monotherapy/Combination Products, H1 2016 14 Number of Products by Stage and Mechanism of Action, H1 2016 15 Number of Products by Stage and Route of Administration, H1 2016 17 Number of Products by Stage and Molecule Type, H1 2016 19 Pipeline by Genentech, Inc., H1 2016 20 Pipeline by Protagonist Therapeutics Inc., H1 2016 21 Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 22 Dormant Projects, H1 2016 34 Discontinued Products, H1 2016 35
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
